Precision Neuroscience has raised $250M in a round that values the New York brain-implant developer at just over $1B and lifts its total funding to $430M.
The company’s Layer 7 Cortical Interface is a film thinner than a human hair that rests on the brain’s surface and slides through a slit in the skull less than a millimetre wide, rather than threading electrodes into tissue the way Neuralink does. Precision argues that makes the implant reversible, and regulators have cleared it for up to 30 days of use. The company says it has run more than 100 procedures across 18 institutions, including Mount Sinai and Penn Medicine.
Pershing Square and the Institute for Progress contributed $42.5M, with Duquesne Family Office, ARK Invest, B Capital, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital also joining.
The category’s other contenders are flush as well. Elon Musk’s Neuralink banked $600M at a $9B valuation, Synchron’s Series D brought in $200M, and Science Corporation closed a round of its own. None of them has answered the question that decides the field: whether a permanent implant can clear the FDA, and whether patients will accept one resting on their brain for years rather than weeks.
Rivals in the category are raising heavily too. Neuralink banked $600M at a $9B valuation, Synchron collected $200M in a Series D, and Science Corporation closed a round of its own. Nobody has yet answered whether any of them can win permanent FDA clearance for a device patients would keep for years rather than weeks.
